Advertisement

European Journal of Clinical Pharmacology

, Volume 74, Issue 4, pp 513–520 | Cite as

The limitations of some European healthcare databases for monitoring the effectiveness of pregnancy prevention programmes as risk minimisation measures

  • R. A. Charlton
  • V. Bettoli
  • H. J. Bos
  • A. Engeland
  • E. Garne
  • R. Gini
  • A. V. Hansen
  • L. T. W. de Jong-van den berg
  • S. Jordan
  • K. Klungsøyr
  • A. J. Neville
  • A. Pierini
  • A. Puccini
  • M. Sinclair
  • D. Thayer
  • H. Dolk
Pharmacoepidemiology and Prescription
  • 264 Downloads

Abstract

Purpose

Pregnancy prevention programmes (PPPs) exist for some medicines known to be highly teratogenic. It is increasingly recognised that the impact of these risk minimisation measures requires periodic evaluation. This study aimed to assess the extent to which some of the data needed to monitor the effectiveness of PPPs may be present in European healthcare databases.

Methods

An inventory was completed for databases contributing to EUROmediCAT capturing pregnancy and prescription data in Denmark, Norway, the Netherlands, Italy (Tuscany/Emilia Romagna), Wales and the rest of the UK, to determine the extent of data collected that could be used to evaluate the impact of PPPs.

Results

Data availability varied between databases. All databases could be used to identify the frequency and duration of prescriptions to women of childbearing age from primary care, but there were specific issues with availability of data from secondary care and private care. To estimate the frequency of exposed pregnancies, all databases could be linked to pregnancy data, but the accuracy of timing of the start of pregnancy was variable, and data on pregnancies ending in induced abortions were often not available. Data availability on contraception to estimate compliance with contraception requirements was variable and no data were available on pregnancy tests.

Conclusion

Current electronic healthcare databases do not contain all the data necessary to fully monitor the effectiveness of PPP implementation, and thus, special data collection measures need to be instituted.

Keywords

Pregnancy Teratogen Pregnancy prevention programme Electronic health records Isotretinoin 

Notes

Acknowledgements

The authors wish to thank Professor Corinne de Vries for her valuable contribution to the initial stages of this work. The authors would also like to acknowledge the input from the EUROmediCAT Steering Group members who reviewed this paper.

Funding

This study was part of the EUROmediCAT research project (www.euromedicat.eu) which has been supported by the European Commission under the 7th Framework Programme Grant agreement n° 260598.

Compliance with ethical standards

Conflicts of interest

RA Charlton, HJ Bos, E Garne, AV Hansen, LTW de Jong-van den berg, S Jordan, K Klungsøyr, A Pierini, M Sinclair, D Thayer and H Dolk had financial support from the European Union for the submitted work under the 7th Framework Programme (Grant agreement HEALTH-F5-2011-260598). AJ Neville was paid as a consultant to the Retinoids Consensus Conference and works for the IMER Registry which is financed by the Emilia Romagna Health Authority. V Bettoli, A Engeland, R Gini and A Puccini have no conflicts of interest to report relevant to the content of this manuscript.

Supplementary material

228_2017_2398_MOESM1_ESM.docx (17 kb)
Table S1 (DOCX 17 kb).

References

  1. 1.
    European Medicine Agency (EMA) (2017) Guideline on good pharmacovigilance practices (GVP) module V—risk management systems (Rev 2). [cited 2017 05 July]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129134.pdf
  2. 2.
    European Medicines Agency (2015) Towards optimising risk minimisation measures. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Report/2015/12/WC500198810.pdf. Accessed 07.05.2017
  3. 3.
    Whitley L, Knight C, Gabbay F Risk minimisation and measuring effectiveness—the evolving challenge. Available from www.transcrip-partners.com/files/download/78. Accessed 07.07.2017
  4. 4.
    Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT, Curry CJ, Fernhoff PM, Grix AW Jr, Lott IT, Richard JM, Sun SC (1985) Retinoic acid embryopathy. N Engl J Med 313(14):837–841.  https://doi.org/10.1056/NEJM198510033131401 CrossRefPubMedGoogle Scholar
  5. 5.
    McBride W (1961) Thalidomide and congenital abnormalities. Lancet 2:1358CrossRefGoogle Scholar
  6. 6.
    Howard WB, Willhite CC (1986) Toxicity of retinoids in humans and animals. J Toxicol Toxin Rev 5(1):55–94CrossRefGoogle Scholar
  7. 7.
    Bonebrake R, Casey MJ, Huerter C, Ngo B, O’Brien R, Rendell M (2008) Ethical challenges of pregnancy prevention programs. Cutis 81(6):494–500PubMedGoogle Scholar
  8. 8.
    Roche Products (Ireland) Limited (2016) Roaccutane: pregnancy prevention programme. Physician’s guide to prescribing isotretinoin (Roaccutane) Available from https://www.hpra.ie/docs/default-source/3rd-party-documents/educational-materials/roaccutane-prescriber-guide.pdf?sfvrsn=2. Accessed 08/06/2016
  9. 9.
    Acitretin summary of product characteristics (2015) Available from http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1463720374780.pdf. Accessed 09.06/2016
  10. 10.
    Crijns I, Zomerdijk I, Sturkenboom M, de Jong-van den Berg L, Straus S (2014) A comparison of pregnancy prevention programmes in Europe. Expert Opin Drug Saf 13(4):411–420.  https://doi.org/10.1517/14740338.2014.887678 CrossRefPubMedGoogle Scholar
  11. 11.
    Crijns HJ, Straus SM, Gispen-de Wied C, de Jong-van den Berg LT (2011) Compliance with pregnancy prevention programmes of isotretinoin in Europe: a systematic review. Br J Dermatol 164(2):238–244.  https://doi.org/10.1111/j.1365-2133.2010.09976.x CrossRefPubMedGoogle Scholar
  12. 12.
    Raguideau F, Mezzarobba M, Zureik M, Weill A, Ricordeau P, Alla F (2015) Compliance with pregnancy prevention plan recommendations in 8672 French women of childbearing potential exposed to acitretin. Pharmacoepidemiol Drug Saf 24(5):526–533.  https://doi.org/10.1002/pds.3763 CrossRefPubMedGoogle Scholar
  13. 13.
    Henry D, Dormuth C, Winquist B, Carney G, Bugden S, Teare G, Lévesque LE, Bérard A, Paterson JM, Platt RW, CNODES (Canadian Network for Observational Drug Effect Studies) Investigators (2016) Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapy. CMAJ: Can Med Assoc J 188(10):723–730.  https://doi.org/10.1503/cmaj.151243 CrossRefGoogle Scholar
  14. 14.
    Charlton RA, Neville AJ, Jordan S, Pierini A, Damase-Michel C, Klungsøyr K, Andersen AMN, Hansen AV, Gini R, Bos JHJ, Puccini A, Hurault-Delarue C, Brooks CJ, de Jong-van den Berg LTW, de Vries CS (2014) Healthcare databases in Europe for studying medicine use and safety during pregnancy. Pharmacoepidemiol Drug Saf 23(6):586–594.  https://doi.org/10.1002/pds.3613 CrossRefPubMedGoogle Scholar
  15. 15.
    Dolk H (2005) EUROCAT: 25 years of European surveillance of congenital anomalies. Arch Dis Child Fetal Neonatal Ed 90(5):F355–F3F8.  https://doi.org/10.1136/adc.2004.062810 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Lynge E, Sandegaard JL, Rebolj M (2011) The Danish National Patient Register. Scand J Public Health 39(7 suppl):30–33.  https://doi.org/10.1177/1403494811401482 CrossRefPubMedGoogle Scholar
  17. 17.
    Wallach Kildemoes H, Toft Sørensen H, Hallas J (2011) The Danish National Prescription Registry. Scand J Public Health. 39(7 suppl):38–41.  https://doi.org/10.1177/1403494810394717 CrossRefGoogle Scholar
  18. 18.
    Thygesen LC, Daasnes C, Thaulow I, Brønnum-Hansen H (2011) Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, and archiving. Scand J Public Health. 39(7 suppl):12–16.  https://doi.org/10.1177/1403494811399956 CrossRefPubMedGoogle Scholar
  19. 19.
    Schirm E, Tobi H, de Jong-van den Berg LTW (2004) Identifying parents in pharmacy data: a tool for the continuous monitoring of drug exposure to unborn children. J Clin Epidemiol 57(7):737–741.  https://doi.org/10.1016/j.jclinepi.2002.12.001 CrossRefPubMedGoogle Scholar
  20. 20.
    Bakker MK, Jentink J, Vroom F, Van Den Berg PB, De Walle HE, De Jong-Van Den Berg LT (2006) Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG 113(5):559–568.  https://doi.org/10.1111/j.1471-0528.2006.00927.x CrossRefPubMedGoogle Scholar
  21. 21.
    Espnes MG, Bjørge T, Engeland A (2011) Comparison of recorded medication use in the Medical Birth Registry of Norway with prescribed medicines registered in the Norwegian Prescription Database. Pharmacoepidemiol Drug Saf 20(3):243–248.  https://doi.org/10.1002/pds.2085 CrossRefPubMedGoogle Scholar
  22. 22.
    Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT (2010) The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 106(2):86–94.  https://doi.org/10.1111/j.1742-7843.2009.00494.x CrossRefPubMedGoogle Scholar
  23. 23.
    Klungsøyr K, Morken NH, Irgens L, Vollset SE, Skjærven R (2012) Secular trends in the epidemiology of pre-eclampsia throughout 40 years in Norway: prevalence, risk factors and perinatal survival. Paediatr Perinat Epidemiol 26(3):190–198.  https://doi.org/10.1111/j.1365-3016.2012.01260.x CrossRefPubMedGoogle Scholar
  24. 24.
    Coloma PM, Schuemie MJ, Trifirò G, Gini R, Herings R, Hippisley-Cox J, Mazzaglia G, Giaquinto C, Corrao G, Pedersen L, van der Lei J, Sturkenboom M, on behalf of the EU-ADR consortium (2011) Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf 20(1):1–11.  https://doi.org/10.1002/pds.2053 CrossRefPubMedGoogle Scholar
  25. 25.
    Coloma PM, Trifirò G, Schuemie MJ, Gini R, Herings R, Hippisley-Cox J, Mazzaglia G, Picelli G, Corrao G, Pedersen L, Lei J, Sturkenboom M, on behalf of the EU-ADR consortium (2012) Electronic healthcare databases for active drug safety surveillance: is there enough leverage? Pharmacoepidemiol Drug Saf 21(6):611–621.  https://doi.org/10.1002/pds.3197 CrossRefPubMedGoogle Scholar
  26. 26.
    Gagne JJ, Maio V, Berghella V, Louis DZ, Gonnella JS (2008) Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy. Eur J Clin Pharmacol 64(11):1125–1132.  https://doi.org/10.1007/s00228-008-0546-y CrossRefPubMedGoogle Scholar
  27. 27.
    Ford D, Jones K, Verplancke J-P, Lyons R, John G, Brown G et al (2009) The SAIL Databank: building a national architecture for e-health research and evaluation. BMC Health Serv Res 9(1):157.  https://doi.org/10.1186/1472-6963-9-157 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Lyons R, Jones K, John G, Brooks C, Verplancke J-P, Ford D et al (2009) The SAIL databank: linking multiple health and social care datasets. BMC Med Inform Decis Mak 9(1):3.  https://doi.org/10.1186/1472-6947-9-3 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Wood L, Martinez C (2004) The general practice research database: role in pharmacovigilance. Drug Saf 27(12):871–881.  https://doi.org/10.2165/00002018-200427120-00004 CrossRefPubMedGoogle Scholar
  30. 30.
    Charlton RA, Snowball J, Sammon CJ, de Vries CS (2013) The clinical practice research datalink for drug safety in pregnancy research: an overview. Therapie 69(1):83–89CrossRefGoogle Scholar
  31. 31.
    Goodfield MJ, Cox NH, Bowser A, McMillan JC, Millard LG, Simpson NB et al (2010) Advice on the safe introduction and continued use of isotretinoin in acne in the U.K. 2010. Br J Dermatol 162(6):1172–1179.  https://doi.org/10.1111/j.1365-2133.2010.09836.x CrossRefPubMedGoogle Scholar
  32. 32.
    Medicines Healthcare products Regulatory Agency (2014) Guidance—isotretinoin for severe acne: uses and effects. Available from https://www.gov.uk/government/publications/isotretinoin-for-severe-acne-uses-and-effects/isotretinoin-for-severe-acne-uses-and-effects. Accessed 19.07.2017
  33. 33.
    Schaefer C, Meister R, Weber-Schoendorfer C (2010) Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy. Arch Gynecol Obstet 281(2):221–227.  https://doi.org/10.1007/s00404-009-1112-2 CrossRefPubMedGoogle Scholar
  34. 34.
    de Jonge L, Garne E, Gini R, Jordan SE, Klungsoyr K, Loane M, Neville AJ, Pierini A, Puccini A, Thayer DS, Tucker D, Vinkel Hansen A, Bakker MK (2015) Improving information on maternal medication use by linking prescription data to congenital anomaly registers: a EUROmediCAT study. Drug Saf 38(11):1083–1093.  https://doi.org/10.1007/s40264-015-0321-9 CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Lagan BM, Dolk H, White B, Uges DRA, Sinclair M (2014) Assessing the availability of the teratogenic drug isotretinoin outside the pregnancy prevention programme: a survey of e-pharmacies. Pharmacoepidemiol Drug Saf 23(4):411–418.  https://doi.org/10.1002/pds.3565 CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Holmes, Bankowska, Mackie (1998) The prescription of isotretinoin to women: is every precaution taken? Br J Dermatol 138(3):450–455.  https://doi.org/10.1046/j.1365-2133.1998.02123.x CrossRefPubMedGoogle Scholar
  37. 37.
    Wildfang I, Nielsen N, Jemec G, Ibsen H, Avnstorp C (2002) Isotretinoin in Denmark—20 years on. J Dermatolog Treat 13(3):151–152.  https://doi.org/10.1080/09546630260199532 CrossRefPubMedGoogle Scholar
  38. 38.
    Crijns I, Mantel-Teeuwisse A, Bloemberg R, Pinas E, Straus S, de Jong-van den Berg L (2013) Healthcare professional surveys to investigate the implementation of the isotretinoin Pregnancy Prevention Programme: a descriptive study. Expert Opin Drug Saf 12(1):29–38.  https://doi.org/10.1517/14740338.2013.745850 CrossRefPubMedGoogle Scholar
  39. 39.
    Källén B (1999) Restriction of the use of drugs with teratogenic properties: Swedish experiences with isotretinoin. Teratology 60(2):53.  https://doi.org/10.1002/(SICI)1096-9926(199908)60:2<53::AID-TERA2>3.0.CO;2-7 CrossRefPubMedGoogle Scholar
  40. 40.
    De Santis M, Straface G, Cavaliere A, Nobili E, Caruso A (2007) The need for restricted prescription of retinoic acid derivative isotretinoin to prevent retinoid teratogenicity. Prev Med 45(2–3):243–244.  https://doi.org/10.1016/j.ypmed.2007.04.010 CrossRefPubMedGoogle Scholar
  41. 41.
    Crijns HJMJ, van Rein N, Gispen-de Wied CC, Straus SM, de Jong-van den Berg LTW (2012) Prescriptive contraceptive use among isotretinoin users in the Netherlands in comparison with non-users: a drug utilisation study. Pharmacoepidemiol Drug Saf 21(10):1060–1066.  https://doi.org/10.1002/pds.3200 CrossRefPubMedGoogle Scholar
  42. 42.
    Teichert M, Visser L, Dufour M, Rodenburg E, Straus SJM, Smet PGM et al (2010) Isotretinoin use and compliance with the Dutch Pregnancy Prevention Programme. Drug Saf 33(4):315–326.  https://doi.org/10.2165/11319190-000000000-00000 CrossRefPubMedGoogle Scholar
  43. 43.
    Zomerdijk IM, Ruiter R, Houweling LMA, Herings RMC, Sturkenboom MCJM, Straus SMJM, Stricker BH (2014) Isotretinoin exposure during pregnancy: a population-based study in The Netherlands. BMJ Open 4(11):e005602.  https://doi.org/10.1136/bmjopen-2014-005602 CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    European Medicines Agency. Valproate and related substances and their use in pregnant women. [Cited 08/07/2016] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Valproate_and_related_substances_31/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500175214.pdf. Accessed 07.07.2017

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Authors and Affiliations

  • R. A. Charlton
    • 1
  • V. Bettoli
    • 2
  • H. J. Bos
    • 3
  • A. Engeland
    • 4
    • 5
  • E. Garne
    • 6
  • R. Gini
    • 7
  • A. V. Hansen
    • 8
  • L. T. W. de Jong-van den berg
    • 3
  • S. Jordan
    • 9
  • K. Klungsøyr
    • 5
    • 10
  • A. J. Neville
    • 11
  • A. Pierini
    • 12
  • A. Puccini
    • 13
  • M. Sinclair
    • 14
  • D. Thayer
    • 15
  • H. Dolk
    • 14
  1. 1.Department of Pharmacy and PharmacologyUniversity of BathBathUK
  2. 2.Department of Clinical and Experimental Medicine, Section of DermatologyUniversity of FerraraFerraraItaly
  3. 3.Pharmacoepidemiology and Pharmacoeconomics Unit, Department of PharmacyUniversity of GroningenGroningenThe Netherlands
  4. 4.Department of PharmacoepidemiologyThe Norwegian Institute of Public HealthOsloNorway
  5. 5.Department of Global Public Health and Primary CareUniversity of BergenBergenNorway
  6. 6.Paediatric DepartmentHospital LillebaeltKoldingDenmark
  7. 7.Agenzia Regionale di Sanità della ToscanaFlorenceItaly
  8. 8.Department of Public HealthUniversity of CopenhagenCopenhagenDenmark
  9. 9.Department of Nursing, College of Human and Health SciencesSwansea UniversitySwanseaUK
  10. 10.Domain for Health Data and DigitalisationThe Norwegian Institute of Public HealthOsloNorway
  11. 11.IMER (Emilia Romagna Registry of Birth Defects), Centre for Clinical and Epidemiological ResearchUniversity of Ferrara and Azienda Ospedaliero-Universitaria di FerraraFerraraItaly
  12. 12.Institute of Clinical Physiology-National Research Council (IFC-CNR)/Fondazione Toscana “Gabriele Monasterio”PisaItaly
  13. 13.Drug Policy ServiceEmilia Romagna Region Health AuthorityBolognaItaly
  14. 14.University of Ulster, Institute of Nursing and Health ResearchNewtownabbeyNorthern Ireland
  15. 15.School of MedicineSwansea UniversitySwanseaUK

Personalised recommendations